Clinical Trial Update: Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of brentuximab vedotin in relapsed/refractory germ cell tumors was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embryonal Carcinoma
• Germ Cell Tumor
• Nonseminomatous Germ Cell Tumor
• Testicular Cancer

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Nabil Adra | Conditions: Germ Cell Tumors, Testis Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-11-26